Evercore ISI lowered the firm’s price target on Travere Therapeutics (TVTX) to $35 from $45 and keeps an Outperform rating on the shares. All eyes are on the FSGS PDUFA on January 13, 2026, given that this has “implications for the whole renal field,” according to the analyst, who sees this as an up 30%-35% or down 60%-65% event for Travere.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- FILSPARI Positioned as Foundational Therapy for IgAN Following KDIGO Guidelines and PROTECT Study Validation
- Target initiated, Nike upgraded: Wall Street’s top analyst calls
- Travere Therapeutics price target raised to $25 from $20 at Stifel
- Travere Therapeutics falls -6.6%
- Travere Therapeutics price target raised to $35 from $27 at Wells Fargo